Ceva Animal Health (Ceva), the world’s fifth-largest animal health company, opens Biogenovac, its brand-new genomics research laboratory, in Beaucouzé (Maine-et-Loire), France. The laboratory, which is partly financed by the French government as part of its recovery plan and the Pays de la Loire region, reinforces Ceva’s commitment to preventing future health crises by anticipating variations in viral strains and combating emerging animal diseases.
Innovative technologies to design and produce the vaccines of the future to combat emerging diseases
Responding to the challenges posed by the rise of new epizootics, this new technological platform will enable Ceva to develop effective, industrialized, and competitive vaccine solutions capable of rapidly responding to the rise of emerging infectious diseases. With this investment, Ceva confirms its leadership in animal health research and innovation and its commitment to the One Health concept.
This new platform is equipped with cutting-edge technological innovations incorporating the latest high-throughput sequencing and bioinformatics techniques for developing nucleotide vaccines:The site boasts a centralized bioinformatics interface facilitating the detailed analysis and processing of a large volume of vaccine data (coverage, efficacy, antigen design, etc.). This will enable vaccines to be adapted as closely as possible to the realities of the field, thereby enhancing their effectiveness.
Present in 47 countries with 21 R&D centres across the globe, Ceva is deeply attached to global health and industrial sovereignty and plays an active role in it investing 10% of its turnover annually into R&D endeavours. This initiative is a unique opportunity to develop effective, safe and scientifically innovative responses to the major diseases affecting our livestock. Commenting on the inauguration, Marc Prikazsky, Chairman and CEO of Ceva Animal Health, said: “The inauguration of Biogenovac is a decisive step for Ceva and our ability to continue innovating for the future of animal vaccination. This project testifies to our determination to support breeders by developing tailor-made solutions to emerging diseases. This investment also embodies our commitment to the dynamism of our regions and to our health and industrial sovereignty.”
Related posts
